RxSight, Inc. achieved a 41% increase in Q4 2024 revenue to $40.2 million, primarily due to a 61% rise in LAL procedure volume and a 46% expansion in LDD installed base. The company also reported a significant improvement in net loss and gross profit margin compared to the previous year.
Fourth quarter 2024 revenue increased by 41% to $40.2 million, compared to $28.6 million in Q4 2023.
Gross profit for Q4 2024 was $28.8 million, or 71.6% of revenue, up from $17.7 million or 61.8% in Q4 2023.
Net loss for Q4 2024 improved to $(5.9) million, or $(0.15) per share, from $(9.2) million, or $(0.26) per share, in Q4 2023.
Adjusted net earnings for Q4 2024 were $1.3 million, or $0.03 per share, compared to an adjusted net loss of $(4.8) million, or $(0.13) per share, in Q4 2023.
RxSight, Inc. reiterated its full-year 2025 guidance, projecting continued growth in revenue and gross profit margin, while managing operating expenses.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance